Reviewing HUTCHMED (NASDAQ:HCM) and Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Risk and Volatility

Autolus Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Earnings and Valuation

This table compares Autolus Therapeutics and HUTCHMED”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$10.12 million	38.40	-$220.66 million	($0.83)	-1.76
HUTCHMED	$548.51 million	4.51	$456.91 million	N/A	N/A

HUTCHMED has higher revenue and earnings than Autolus Therapeutics.

Institutional & Insider Ownership

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Autolus Therapeutics and HUTCHMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-439.69%	-63.76%	-30.88%
HUTCHMED	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and price targets for Autolus Therapeutics and HUTCHMED, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	2	0	5	0	2.43
HUTCHMED	1	3	1	1	2.33

Autolus Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 482.19%. HUTCHMED has a consensus price target of $16.88, indicating a potential upside of 18.92%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Autolus Therapeutics is more favorable than HUTCHMED.

Summary

Autolus Therapeutics beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.